Skip to main content

Advertisement

Log in

The Diverse Roles of Anticonvulsants in Bipolar Disorders

  • Published:
Annals of Clinical Psychiatry

Abstract

Anticonvulsant drugs (ACs) have diverse antiseizure, psychotropic, and biochemical effects. Carbamazepine and valproate have mood-stabilizing actions, benzodiazepines and gabapentin have anxiolytic actions, lamotrigine is useful in rapid cycling and acute treatment and prophylaxis of bipolar depression, and topiramate and zonisamide can yield weight loss. Limited controlled data suggest the carbamazepine keto derivative oxcarbazepine has antimanic effects. A categorical approach to the diverse roles of ACs in bipolar disorders is proposed, using broad categories of ACs, on the basis of their predominant psychotropic profiles. Thus, some ACs have “sedating” profiles that may include sedation, cognitive difficulties, fatigue, weight gain, and possibly antimanic and/or anxiolytic effects. In contrast, some newer ACs have “activating” profiles that may include improved energy, weight loss, and possibly antidepressant and even anxiogenic effects. Still other newer ACs have novel “mixed” profiles, combining sedation and weight loss. A categorical–mechanistic extension of this approach is also presented, with hypotheses that “sedating” profiles might be related to prominent potentiation of gamma-aminobutyric acid (GABA) inhibitory neurotransmission, “activating” profiles could be related to prominent attenuation of glutamate excitatory neurotransmission, and for “mixed” profiles, sedation and weight loss might be related to concurrent GABAergic and antiglutamatergic actions, respectively. The categorical approach may have utility as an aid to clinicians in reinforcing the heterogeneity ACs, and recalling psychotropic profiles of individual ACs, but is limited as it fails to address the etiology of the heterogeneity of AC psychotropic effects. The categorical–mechanistic extension strives to address this issue, but requires systematic clinical investigation of more precise relationships between psychotropic profiles and discrete mechanisms of action to assess its merits.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Ketter TA, Kimbrell TA, George MS, Sachs N, Wang PW, Post RM: Predictors of treatment response in bipolar disorder: Evidence from clinical and PET studies. J Clin Psychiatry 2002; 63(Suppl 3):21-25

    Google Scholar 

  2. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(4 Suppl):1-50

    Google Scholar 

  3. Petty F: GABA and mood disorders: A brief review and hypothesis. J Affect Disord 1995; 34(4):275-281

    Google Scholar 

  4. Motohashi N, Ikawa K, Kariya T: GABAB receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders? Eur J Pharmacol 1989; 166(1):95-99

    Google Scholar 

  5. Motohashi N: GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16(4):571-579

    Google Scholar 

  6. Bernasconi R: The GABA hypothesis of affective illness: Influence of clinically effective antimanic drugs on GABA turnover. In: Emrich HM, Aidenhoff JB, Lux HD, eds. Basic Mechanisms in the Action of Lithium, Proceedings of a symposium, Bavaria, Oct 4–6, 1981. Amsterdam: Elsevier Science; 1982:183-192

  7. Bernasconi R, Hauser K, Martin P, Shcmutz M: Biochemical aspects of the mechanism of action of valproate. In: Emrich HM, Okuma T, Müller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam: Elsevier Science; 1984:14-32

  8. Post RM, Ketter TA, Joffe RT, Kramlinger KL: Lack of beneficial effects of l-baclofen in affective disorder. Int Clin Psychopharmacol 1991; 6(4):197-207

    Google Scholar 

  9. Pope HG, Jr, McElroy SL, Keck PE, Jr, Hudson JI: Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991; 48(1):62-68

    Google Scholar 

  10. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Treviño ES, Risch SC, Goodnick PJ, Morris DD: (The Depakote Mania Study Group): Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271(12):918-924

    Google Scholar 

  11. Winsberg ME, DeGolia SG, Strong CM, Ketter TA: Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67(1–3):207-212

    Google Scholar 

  12. Ketter TA, Calabrese JR: Stabilization of mood from below versus above baseline in bipolar disorder: A new nomenclature. J Clin Psychiatry 2002; 63(2):146-151

    Google Scholar 

  13. Andersen T, Lingjaerde O: Nitrazepam (Mogadon) as a sleep-inducing agent. An analysis based on a double-blind comparison with phenobarbitone. Br J Psychiatry 1969; 115(529):1393-1397

    Google Scholar 

  14. Ballenger JC, Burrows GD, DuPont RL, Jr, Lesser IM, Noyes R, Jr, Pecknold JC, Rifkin A, Swinson RP: Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial, I: Efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45(5):413-422

    Google Scholar 

  15. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM: Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19(4):341-348

    Google Scholar 

  16. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T: Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20(4):467-471

    Google Scholar 

  17. Bradwejn J, Shriqui C, Koszycki D, Meterissian G: Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990; 10(6):403-408

    Google Scholar 

  18. Pande AC, Crockatt J, Janney CA, Werth JL, Tsaroucha G (Gabapentin Bipolar Disorder Study Group): Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000; 2(3, pt 2):249-255

    Google Scholar 

  19. Rickels K, Chung HR, Csanalosi IB, Hurowitz AM, London J, Wiseman K, Kaplan M, Amsterdam JD: Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry 1987; 44(10):862-866

    Google Scholar 

  20. Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA: Gabapentin augmentation therapy in bipolar depression. Bipolar Disord 2002; 4(5):296-301

    Google Scholar 

  21. Kaiya H, Namba M, Yoshida H, Nakamura S: Plasma glutamate decarboxylase activity in neuropsychiatry. Psychiatry Res 1982; 6(3):335-343

    Google Scholar 

  22. Nowak G, Ordway GA, Paul IA: Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995; 675(1–2):157-164

    Google Scholar 

  23. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F: Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000; 47(4):305-313

    Google Scholar 

  24. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158(9):1367-1377

    Google Scholar 

  25. Cai Z, McCaslin PP: Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate-and N-methyl-D-aspartate-induced intracellular Ca2+ levels in neuronal culture. Eur J Pharmacol 1992; 219(1):53-57

    Google Scholar 

  26. Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA: Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993; 265(3):1380-1386

    Google Scholar 

  27. Gottesfeld Z: Effect of lithium and other alkali metals on brain chemistry and behavior, I: Glutamic acid and GABA in brain regions. Psychopharmacologia 1976; 45(3):239-242

    Google Scholar 

  28. Marcus SR, Nadiger HA, Chandrakala MV, Rao TI, Sadasivudu B: Acute and short-term effects of lithium on glutamate metabolism in rat brain. Biochem Pharmacol 1986; 35(3):365-369

    Google Scholar 

  29. Hokin LE, Dixon JF, Los GV: A novel action of lithium: Stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices. Adv Enzyme Regul 1996; 36:229-244

    Google Scholar 

  30. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD: (Lamictal 602 Study Group): A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60(2):79-88

    Google Scholar 

  31. Twyman RE, Rogers CJ, Macdonald RL: Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25(3):213-220

    Google Scholar 

  32. MacKinnon DF, Zandi PP, Cooper J, Potash JB, Simpson SG, Gershon E, Nurnberger J, Reich T, DePaulo JR: Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry 2002; 159(1):30-35

    Google Scholar 

  33. Lampe H, Bigalke H: Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport 1990; 1(1):26-28

    Google Scholar 

  34. Post RM: Time course of clinical effects of carbamazepine: Implications for mechanisms of action. J Clin Psychiatry 1988; 49(4 Suppl):35-48

    Google Scholar 

  35. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP: Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002; 27(1–2):121-130

    Google Scholar 

  36. Ketter TA, Post RM, Pazzaglia PJ, Marangell LB, George MS, Callahan AM: Carbamazepine. In: Goodnick P, ed. Mania: Clinical and Research Perspectives. Washington: American Psychiatric Press: 1998:263-300

  37. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT: Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143(1):29-34

    Google Scholar 

  38. Uhde TW, Stein MB, Post RM: Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988; 145(9):1104-1109

    Google Scholar 

  39. Mattson RH, Cramer JA, Collins JF: (The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group): A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327(11):765-771

    Google Scholar 

  40. Rattya J, Vainionpaa L, Knip M, Lanning P, Isojarvi JI: The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999; 103(3):588-593

    Google Scholar 

  41. Ketter TA, Post RM, Worthington K: Principles of clinically important drug interactions with carbamazepine, Part I. J Clin Psychopharmacol 1991; 11(3):198-203

    Google Scholar 

  42. Ketter TA, Post RM, Worthington K: Principles of clinically important drug interactions with carbamazepine, Part II. J Clin Psychopharmacol 1991; 11(5):306-313

    Google Scholar 

  43. Tohen M, Castillo J, Baldessarini RJ, Zarate C, Jr, Kando JC: Blood dyscrasias with carbamazepine and valproate: A pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995; 152(3):413-418

    Google Scholar 

  44. Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B: Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18(6):455-460

    Google Scholar 

  45. Löscher W: Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999; 58(1):31-59

    Google Scholar 

  46. Keck PE, Jr, Taylor VE, Tugrul KC, McElroy SL, Bennett JA: Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993; 33(7):542-546

    Google Scholar 

  47. Hirschfeld RM, Allen MH, McEvoy JP, Keck PE, Jr, Russell JM: Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999; 60(12):815-818

    Google Scholar 

  48. Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, Calabrese JR, Goodnick P, Small JG, Rush AJ, Kimmel SE, Risch SC, Morris DD: Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153(6):765-770

    Google Scholar 

  49. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Jr, Chou JC, Keck PE, Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ (Divalproex Maintenance Study Group): A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57(5):481-489

    Google Scholar 

  50. Ketter TA, Malow BA, Flamini R, Ko D, White SR, Post RM, Theodore WH: Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 1996; 23(2):129-137

    Google Scholar 

  51. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH: The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39(1):95-99

    Google Scholar 

  52. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29(3):233-249

    Google Scholar 

  53. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271(10):5768-5776

    Google Scholar 

  54. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Corá-Locatelli G, Leverich GS, Post RM: A placebo controlled evaluation of lamotrigine and gabapentin monotherapy in mood disorders. J Clin Psychopharmacology 2000; 20(4):607-614

    Google Scholar 

  55. Frye MA, Kimbrell TA, Dunn RT, Piscitelli S, Grothe D, Vanderham E, Corá-Locatelli G, Post RM, Ketter TA: Gabapentin does not alter single-dose lithium pharmacokinetics. J Clin Psychopharmacol 1998; 18(6):461-464

    Google Scholar 

  56. Backonja MM: Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: A multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia 1999; 40(Suppl 6):S57-S59

    Google Scholar 

  57. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L: Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998; 280(21):1837-1842

    Google Scholar 

  58. Xie X, Hagan RM: Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38(3):119-130

    Google Scholar 

  59. Ketter TA, Manji HK, Post RM: Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol (in press)

  60. Marson AG, Kadir ZA, Hutton JL, Chadwick DW: The new antiepileptic drugs: A systematic review of their efficacy and tolerability. Epilepsia 1997; 38(8):859-880

    Google Scholar 

  61. Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, Goodwin FK, Frye MA, Kusumakar V: Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management. J Clin Psychiatry 2002; 63(11):1012-1019

    Google Scholar 

  62. Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS: Lamotrigine-induced carbamazepine toxicity: An interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992; 11(2):147-150

    Google Scholar 

  63. Malminiemi K, Keranen T, Kerttula T, Moilanen E, Ylitalo P: Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther 2000; 38(11):540-545

    Google Scholar 

  64. Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, Wolf KB, Wargin WA, Dren AT: Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996; 60(2):145-156

    Google Scholar 

  65. Kaufman KR, Gerner R: Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7(2):163-165

    Google Scholar 

  66. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET (Lamictal 614 Study Group): A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61(11):841-850

    Google Scholar 

  67. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE: An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41(Suppl 1):S3-S9

    Google Scholar 

  68. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997; 28(3):167-179

    Google Scholar 

  69. Petroff OA, Hyder F, Mattson RH, Rothman DL: Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 1999; 52(3):473-478

    Google Scholar 

  70. Kanda T, Kurokawa M, Tamura S, Nakamura J, Ishii A, Kuwana Y, Serikawa T, Yamada J, Ishihara K, Sasa M: Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Life Sci 1996; 59(19):1607-1616

    Google Scholar 

  71. Rosenfeld WE: Topiramate: A review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997; 19(6):1294-1308

    Google Scholar 

  72. Rhee DJ, Goldberg MJ, Parrish RK: Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol 2001; 119(11):1721-1723

    Google Scholar 

  73. Rosenfeld WE, Doose DR, Walker SA, Nayak RK: Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38(3):317-323

    Google Scholar 

  74. Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, Reife R, Kramer L, Pledger G, Karim R: Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37(6):539-543

    Google Scholar 

  75. McElroy SL, Arnold LM, Shapira NA, Keck PE, Jr, Rosenthal NR, Karim MR, Kamin M, Hudson JI: Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial. Am J Psychiatry 2003; 160(2):255-261

    Google Scholar 

  76. Calabrese JR, Keck PE, Jr, McElroy SL, Shelton MD: A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 21(3):340-342

    Google Scholar 

  77. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH: Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disord 2002; 4(3):207-213

    Google Scholar 

  78. Meldrum BS, Chapman AG: Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia 1999; 40(Suppl 9):S2-S6

    Google Scholar 

  79. Kaufman KR: Adjunctive tiagabine treatment of psychiatric disorders: Three cases. Ann Clin Psychiatry 1998; 10(4):181-184

    Google Scholar 

  80. Schaffer L, Schaffer C, Howe J: An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 2002; 71(1–3):259

    Google Scholar 

  81. Physicians' desk reference, 57th ed. Montvale, NJ: Thomson PDR; 2003

  82. Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J: Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60(11):759-762

    Google Scholar 

  83. Schapel G, Chadwick D: Tiagabine and non-convulsive status epilepticus. Seizure 1996; 5(2):153-156

    Google Scholar 

  84. Emrich HM: Studies with (Trileptal) oxcarbazepine in acute mania. Int Clin Psychopharmacology 1990; 5(Suppl 1):83-88

    Google Scholar 

  85. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, Mikkelsen M, Pedersen B, Sabers A, Worm-Petersen J, Andersen D, Jensen PK: Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87(3):224-227

    Google Scholar 

  86. Smith PE: Clinical recommendations for oxcarbazepine. Seizure 2001; 10(2):87-91

    Google Scholar 

  87. Baruzzi A, Albani F, Riva R: Oxcarbazepine: Pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35(3):S14-S19

    Google Scholar 

  88. Keranen T, Jolkkonen J, Jensen PK, Menge GP, Andersson P: Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992; 86(2):120-123

    Google Scholar 

  89. Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E: Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40(6):783-787

    Google Scholar 

  90. Oommen KJ, Mathews S: Zonisamide: A new antiepileptic drug. Clin Neuropharmacol 1999; 22(4):192-200

    Google Scholar 

  91. Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H: Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med J Osaka Univ 1990; 39(1–4):13-17

    Google Scholar 

  92. Okada M, Kawata Y, Mizuno K, Wada K, Kondo T, Kaneko S: Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998; 124(6):1277-1285

    Google Scholar 

  93. Chadwick DW, Marson AG: Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002(2):CD001416

    Google Scholar 

  94. Kanba S, Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki J, Arata E, Koshikawa H, Nibuya M, Kinoshita N, Asai M: The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(4):707-715

    Google Scholar 

  95. Nash EM, Sangha KS: Levetiracetam. Am J Health Syst Pharm 2001; 58(13):1195-1199

    Google Scholar 

  96. Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG: Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001; 10(4):279-286

    Google Scholar 

  97. Fraser CM, Sills GJ, Forrest G, Thompson GG, Brodie MJ: Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. Br J Pharmacol 1999; 126(7):1634-1638

    Google Scholar 

  98. Sills GJ, Leach JP, Fraser CM, Forrest G, Patsalos PN, Brodie MJ: Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur J Pharmacol 1997; 325(1):35-40

    Google Scholar 

  99. Loscher W, Honack D, Bloms-Funke P: The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res 1996; 735(2):208-216

    Google Scholar 

  100. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H: The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA-and glycine-gated currents. Br J Pharmacol 2002; 136(5):659-672

    Google Scholar 

  101. Poulain P, Margineanu DG: Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones. Neuropharmacology 2002; 42(3):346-352

    Google Scholar 

  102. French J, Edrich P, Cramer JA: A systematic review of the safety profile of levetiracetam: A new antiepileptic drug. Epilepsy Res 2001; 47(1–2):77-90

    Google Scholar 

  103. Goldberg JF, Burdick KE: Levetiracetam for acute mania. Am J Psychiatry 2002; 159(1):148

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ketter, T.A., Wang, P.W., Becker, O.V. et al. The Diverse Roles of Anticonvulsants in Bipolar Disorders. Ann Clin Psychiatry 15, 95–108 (2003). https://doi.org/10.1023/A:1024636309185

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024636309185

Navigation